Abstract |
Clinical trials of IL-3, IL-11 and thrombopoietin (TPO) against chemotherapy-induced thrombocytopenia were reviewed. Many clinical trials of IL-3 were conducted, which increased the platelet nadir counts and improved the recovery from thrombocytopenia at a dose of 5 micrograms/kg/day for 7 to 14 days. Major side effects, fever and headache, were tolerable. The combination with G-CSF was also examined. IL-11 improved the platelet nadir counts and the recovery from thrombocytopenia at a dose of 50 micrograms/kg/day for 14 days. Adverse events of IL-11 were general fatigue and edema, which were mild. Phase I/II studies of TPO were conducted, which showed a marked increase of platelet counts and improvement in recovery from thrombocytopenia. A few patients experienced mild thrombo- embolism. Improved QOL and survival benefits in the evaluation of these cytokines must be demonstrated.
|
Authors | S Kudoh, M Yamada |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 25
Issue 2
Pg. 171-6
(Jan 1998)
ISSN: 0385-0684 [Print] Japan |
PMID | 9474925
(Publication Type: English Abstract, Journal Article, Review)
|
Chemical References |
- Interleukin-11
- Interleukin-3
- Granulocyte Colony-Stimulating Factor
- Thrombopoietin
- Carboplatin
- Paclitaxel
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Carboplatin
(adverse effects)
- Carcinoma, Non-Small-Cell Lung
(blood, drug therapy)
- Clinical Trials as Topic
- Clinical Trials, Phase II as Topic
- Drug Administration Schedule
- Granulocyte Colony-Stimulating Factor
(administration & dosage)
- Humans
- Interleukin-11
(administration & dosage)
- Interleukin-3
(administration & dosage)
- Lung Neoplasms
(blood, drug therapy)
- Paclitaxel
(adverse effects)
- Platelet Count
- Randomized Controlled Trials as Topic
- Thrombocytopenia
(chemically induced, therapy)
- Thrombopoietin
(administration & dosage)
- United States
|